Vifor Pharma to propose Åsa Riisberg for appointment to Board of Directors
Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021.
Åsa Riisberg, a Swedish citizen, was formerly Partner and member of the extended Executive Committee of the private equity firm EQT. She has served on various international boards with current board seats at Atlas Antibodies, Netcompany, F-Secure, Dagens Nyheter, Bonnier News and Bonnier Capital as well as at the Women in Finance Foundation. Åsa is also an Advisory Board Member at the Stockholm School of Economics and member of the Investment Committee at Cinder Invest. She holds a M.Sc. in Financial Economics and Business Administration from Stockholm School of Economics.
Jacques Theurillat, Chairman of Vifor Pharma, commented: “We are very pleased that Åsa Riisberg will bring her expertise to the Board of Directors. Her broad knowledge and experience, particularly in the areas of investment management and operations are extremely valuable for Vifor Pharma. She will ideally complement the Board to assess the company’s business development and inorganic growth plans, aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.”
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ID-BRIDGETOWER-CAPITAL15.4.2021 18:02:13 CEST | Press release
BridgeTower Capital Launches Security Token Pre-Offering and Announces Global Expansion With Key Partners
CRYPTOLOGY-ASSET-GROUP-P15.4.2021 16:51:06 CEST | Press release
Cryptology Asset Group p.l.c. successfully completes a share capital increase and sale of treasury shares and reviews options for financing further growth
CRYPTOLOGY-ASSET-GROUP-P15.4.2021 16:47:06 CEST | Press release
Cryptology Asset Group p.l.c. resolves a cash capital increase and sale of treasury shares
TX-MARY-KAY15.4.2021 15:05:08 CEST | Press release
A Digital Transformation: Mary Kay Inc. Launches Immersive Virtual Experience Platform Suite 13TM
CA-CONVIVA15.4.2021 15:02:08 CEST | Press release
Conviva Works With ServiceNow to Provide Next Generation Customer Service for Streaming Customers
THALES15.4.2021 15:02:07 CEST | Press release
Thales IoT SAFE to Secure Cloud Connectivity for New Internet of Things Services in Canada
MA-ABIOMED15.4.2021 14:05:05 CEST | Press release
First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom